Renata PLC announcements
340 Dhaka Stock Exchange announcements for Renata PLC (RENATA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (30).
- Trading of Preference Shares issued by Renata PLC at ATB
DSE is pleased to announce that trading of Preference Shares issued by Renata PLC will commence at DSE from Monday, December 15, 2025 at ATB Platform of DSE. Trading Code of the preference shares is "RENATAPS" and Scrip Code is "47001". Some other salient features of the preference shares are as follows: 1) Issuer: Renata PLC, 2) Issue price: BDT 1,900 per share, 3) Tenure: 6 years from respective subscription completion date, i.e. October 19, 2025, (cont.1) (Continuation news of RENATA): 8) Conversion to ordinary shares: conversion shall start at the end of the 3rd year, 9) Conversion Strike Price: the preference shares shall be converted into ordinary shares at a fixed strike price of BDT. 475 during each conversion period in 4 phases, 10) Circuit breaker: 5% on reference price (issue price). (end) (Continuation news of RENATA): 4) Dividend Rate: 15% on the investment amount not converted to ordinary shares, 5) Return payment frequency: Annual, 6) Nature of the preference shares: Non-cumulative, non-participative and fully convertible, 7) Issue size for listing: BDT 3,250 mn, (cont.2)
- Company Launches Hydrocortisone 5 mg Tablets in the UK Market
The company has informed that it has launched Hydrocortisone 5 mg Tablets in the United Kingdom. Hydrocortisone is an essential corticosteroid indicated for replacement therapy in patients with adrenocortical insufficiency, and the 5 mg strength offers clinicians greater flexibility in titrating doses to mimic physiological cortisol levels, thereby supporting more precise patient management. (cont.) (Cont. News of RENATA): The product is manufactured at Renata's UK MHRA-approved, EU GMP-certified potent facility in Mirpur and will be commercialized under the livery of Renata (UK) Limited. Notably, Renata is among the few companies supplying this strength in the UK market, reaffirming its commitment to expanding access to high-quality endocrine therapies and strengthening its growing presence in global regulated markets. (end)
- Resumption after Record Date
Trading of the shares of the company will resume on 18.11.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 17.11.2025.
- Renata PLC launches Amantadine Capsules in the Nordic Market
The company has informed that it has successfully launched Parkadin (Amantadine 100 mg Capsules) the first and only registered generic of Amantadine in Finland, concurrently introduced in Denmark, Sweden, and Norway. The product, manufactured at their EU-GMP approved Rajendrapur General Facility, is indicated for the symptomatic treatment of Parkinson's disease and (cont.) (Cont. news of RENATA): may be administered as monotherapy or in combination with Levodopa. The launch marks a significant milestone in Renata's global expansion, strengthening its presence across Europe and reinforcing their commitment to providing high-quality, accessible medications worldwide. (end)
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 13.11.2025 to 16.11.2025 and trading of the shares will remain suspended on record date i.e., 17.11.2025.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 6.47 for July-September 2025 as against Tk. 5.19 for July-September 2024. Consolidated NOCFPS was Tk. 12.61 for July-September 2025 as against Tk. (0.04) for July-September 2024. Consolidated NAV per share was Tk. 312.01 as on September 30, 2025 and Tk. 305.49 as on June 30, 2025. Reasons for deviation: Revenue and margin expansion contribution to higher operating profit and EPS increased. (cont.) (Cont. News of RENATA): NOCFPS has increased due to stronger collections and moderated working capital outflows. NAVPS has increased mainly on retained earnings. (end)
- Dividend Declaration
The Board of Directors has recommended 55% Cash Dividend for the year ended June 30, 2025. Date of AGM: 20.12.2025, Time: 11:30 AM, Venue: Digital Platform. Record Date: 17.11.2025. The Company has also reported consolidated EPS of Tk. 19.36, consolidated NAV per share of Tk. 305.49 and consolidated NOCFPS of Tk. 41.16 for the year ended June 30, 2025 as against Tk. 31.53, Tk. 295.56 and Tk. 18.16 respectively for the year ended June 30, 2024.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (28.10.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 27, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 27, 2025 at 03:00 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Credit Rating Result
Alpha Credit Rating PLC. has assigned Surveillance rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook based on audited financial statements up to June 30, 2024; 3rd quarter ended in March 2025 and relevant qualitative information till October 07, 2025.
- Renata PLC delivers Rivaroxaban Capsules to the Australian Market
The company has informed that it has successfully shipped its Rivaroxaban Capsules (15 mg and 20 mg) to Australia, marking the first availability of this important anticoagulant in capsule form in that market. The product has been manufactured at TGA-approved facility, underscoring Renata's commitment to meeting stringent global regulatory standards. This achievement not only broadens patient treatment options in Australia but also reflects Renata's steady progress in expanding its international footprint.
- Company launches first product in the Canadian pharmaceutical market
The company has informed that it has successfully launched its first product in the Canadian pharmaceutical market. The product, Desogestrel/Ethinylestradiol (0.15 mg/0.03 mg) tablets, is being commercialized under the brand names Miley 21 and Miley 28 through a strategic partnership with Ambicare Pharmaceuticals Inc., a well-established Canadian generic pharmaceutical company.
- Renata PLC launches Fludrocortisone in the UK Market
The company has informed that it has launched Fludrocortisone 0.1 mg tablets in the UK market. The product is indicated for partial replacement therapy in primary adrenocortical insufficiency (Addison's disease) and for the treatment of salt-losing adrenogenital syndrome. Fludrocortisone 0.1 mg tablets are being supplied from the Company's UK MHRA-approved (cont.) (Cont. news of RENATA): potent product facility and will be commercialized under the livery of Renata (UK) Limited. Notably, Renata's Fludrocortisone offers a significant advantage with its stability at storage conditions below 25 degree Celsius, in contrast to the innovator product requiring refrigeration between 2-8 degree Celsius. (end)
- Resumption after Record Date
Trading of the shares of the company will resume on 21.08.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 20.08.2025 for EGM.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 18.08.2025 to 19.08.2025 and trading of the shares will remain suspended on record date i.e., 20.08.2025 for EGM.
- Decision regarding EGM & Record Date for issuance of preference shares
Referring to their earlier news disseminated by DSE on 28.07.2025, the company has informed that at the 235th Board Meeting of the company held on July 29, 2025 the Board of Directors has decided to issue Non-Cumulative, Non-Participative and Fully Convertible Preference Shares totaling TK. 3,25,00,00,000/- (Taka three hundred and twenty-five crore) only as directed vide Bangladesh Securities and Exchange Commission (BSEC) Consent Letter (cont.1) (Cont. news of RENATA): Record Date: August 20, 2025 (The shareholders, whose names would appear as shareholders in the Register of Members on the Record Date, shall be entitled to apply for the Non-Cumulative, Non-Participative and Fully Convertible Preference shares, if approved above.). Subscription Period: October 5 to October 9, 2025 (end) (Cont. news of RENATA): Ref: BSEC/CI/CPLC(Public)-1098/2024/491 dated July 27, 2025; subject to approval of the ordinary shareholders of the Company in Extra-Ordinary General Meeting (EGM). Information Regarding EGM is as follows: Date & Time of EGM: September 20, 2025 at 12.00 noon. Venue of EGM: Using Digital Platform. (cont.2)
- Receipt of BSEC Consent regarding Issuance of Preference Shares
The company has informed that they have received the consent letter from the Bangladesh Securities and Exchange Commission (BSEC) for the issuance of Non-Cumulative, Non-Participative and fully convertible preference shares vide letter no. BSEC/CI/CPLC (Public)-1098/2024/49 dated 27 July 2025, subject to approval from the shareholders in Extra-Ordinary General Meeting. In light of this development, the Board of Directors of Renata PLC (cont.1) (Cont. news of RENATA): They have also informed that they will duly notify the Exchange of the outcome of the Board Meeting and provide all relevant disclosures in a timely manner. (end) (Cont. news of RENATA): will convene an immediate meeting to finalize and approve the record date for eligibility of shareholders to attend the EGM and apply for the aforementioned preference shares. Upon determination, the record date will be published in two widely circulated newspapers (one in Bengali and one in English), in compliance with applicable rules and regulations. (cont.2)
- Company achieves EU GMP approval for potent product facility
The company has informed that it has achieves European Union Good Manufacturing Practice (EU GMP) approval for its Mirpur potent product facility. This marks a historic milestone as the first-ever EU GMP approved potent product facility in Bangladesh. The approval was granted following an inspection conducted by the German Regulatory Authority (Competent Authority of Saxony-Anhalt or Landesverwaltungsamt Sachsen-Anhalt). (cont.) (Cont. News of RENATA): The comprehensive certification details are publicly available on the Eudra GMP website. This approval joins the company's existing repertoire of regulatory approvals for multiple facilities from Stringent Regulatory Authorities including UK-MHRA, US-FDA, PIC/S, WHO-PQ, Health Canada, TGA and ANVISA. (end)
- Company receives EU GMP certification for Rajendrapur General Facility
The company has informed that the Rajendrapur General Facility of the compoany has received European Union Good Manufacturing Practice (EU GMP) certification following a comprehensive audit by European authorities.
- Decision to revise structure of proposed issuance of preference share
The company has informed that the Board of Directors, in its 231st meeting held on November 23, 2024 decided to issue Non-Cumulative, Non-Participative, Redeemable or Fully Convertible Preference Shares at the Issuer's discretion, amounting up to BDT 3,250 million. This proposal was duly approved by the shareholders at the Extra Ordinary General Meeting (EGM) held on 12th January 2025. In line with the EGM approval, the Issuer at its discretion through (cont.) (Cont. news of RENATA): the board meeting held on 18th June 2025 has decided to revise the structure in following manner: Previous Structure: Non-Cumulative, Non-Participative, Redeemable or Fully Convertible Preference Shares at Issuer's discretion. Revised Structure: Non-Cumulative, Non-Participative, Fully Convertible Preference Shares. This revision is subject to approval from the Bangladesh Securities and Exchange Commission (BSEC). (end)
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 5.12 for January-March 2025 as against Tk. 6.38 for January-March 2024; Consolidated EPS was Tk. 15.95 for July 2024-March 2025 as against Tk. 22.95 for July 2023-March 2024. Consolidated NOCFPS was Tk. 21.76 for July 2024-March 2025 as against Tk. (1.31) for July 2023-March 2024. Consolidated NAV per share was Tk. 302.49 as on March 31, 2025 and Tk. 295.56 as on June 30, 2024. (Cont.1) (Cont. news of RENATA): Further, increase of depreciation and amortization amounting to BDT 150 million has contributed to the growth of the NOCFPS being a non-operating non-cash adjustment to the profit before tax. (end) (Cont. news of RENATA): Reasons for deviation in NOCFPS: During the nine-month period ended 31 March 2025, the NOCFPS has increased significantly by 17.6 times (by BDT 2.65 billion) compared to the same period of last year mainly for the significant improvement of workings capital underpinned by BDT 2.45 billion lower amount of cash utilization in inventories compared to that of 31 March 2024. (Cont.2)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Regarding launching of Cabergoline 0.5 mg to the UK market
The company has informed that it has successfully shipped first consignment of Cabergoline 0.5 mg tablets to the UK market. This achievement follows its recent launch as the first generic of Cabergoline 0.5 mg in Australia, highlighting the company's growing global presence. Cabergoline, used to treat hyperprolactinemia and Parkinson's disease, is also marketed locally as Cabolin and manufactured at Renata's UK MHRA-approved facility in Bangladesh.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 5.64 for October-December 2024 as against Tk. 7.68 for October-December 2023; Consolidated EPS was Tk. 10.83 for July-December 2024 as against Tk. 16.57 for July-December 2023. Consolidated NOCFPS was Tk. 3.60 for July-December 2024 as against Tk. 2.80 for July-December 2023. Consolidated NAV per share was Tk. 297.23 as on December 31, 2024 and Tk. 295.56 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 25, 2025 at 1:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Renata PLC's First Shipment of Risperidone to the U.S. Market
The company has informed that it has successfully dispatched its first consignment of Risperidone to the USA. Manufactured at Renata's U.S. FDA-approved facility in Bangladesh, Sperid has earned a reputation as a trusted solution for managing psychiatric disorders in the country. The initial shipment of 12 million tablets in 0.25 mg, 0.5 mg, and 1 mg strengths ensures precise dosing, essential for treating schizophrenia, bipolar disorder, and autism-related irritability.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.